Generic Sterile Injectable Market
According to Intent Market Research, the Generic Sterile Injectable Market is expected to grow from USD 38.9 billion in 2024-e at a CAGR of 12.5% to touch USD USD 88.8 Billion billion by 2030. The Generic Sterile Injectable Market is dominated by key players such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG (Sandoz), Mylan N.V. (Viatris), Amgen Inc., Sanofi S.A., Fresenius Kabi AG, Baxter International Inc., Eli Lilly and Co., Boehringer Ingelheim GmbH, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Apotex Inc., Aurobindo Pharma.2030. The Generic Sterile Injectable Market is dominated by key players such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG (Sandoz), Mylan N.V. (Viatris), Amgen Inc., Sanofi S.A., Fresenius Kabi AG, Baxter International Inc., Eli Lilly and Co., Boehringer Ingelheim GmbH, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Apotex Inc., Aurobindo Pharma.